MASLD is commonly associated with obesity and metabolic disturbances, leading to increased systemic inflammation and impaired insulin signaling, thus promoting the development of various metabolic diseases, including MASH and T2DM26. This evidence concerns the gene INS and metabolic dysfunction-associated steatotic liver disease.